18 Nov

On November 17, 2020, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) at the FDA announced additional steps to increase transparency regarding CDER and CBER’s review of the scientific information supporting the issuance of or revisions to an emergency use authorizations (EUAs) to promote public confidence in FDA’s scientific process and the appropriate use of authorized products.

 FDA's intention is to be as transparent as possible under the law about the scientific basis for recommending that a drug or biological product be authorized for emergency use under the Federal Food, Drug and Cosmetic Act.

Source : USFDA

* The email will not be published on the website.